Bispecific Antibodies for Follicular Lymphoma

Opening their discussion on follicular lymphoma, experts Matthew Matasar, MD and Laurie Sehn, MD, reflect on its indolent nature as a subset of non-Hodgkin lymphoma.

Key opinion leaders in the management of follicular lymphoma share their perspective on risk stratification and staging strategies to inform treatment decisionmaking.

A brief review of the role that PET imaging plays in staging follicular lymphoma and how it may inform treatment decisions.

Centering discussion on both symptomatic and asymptomatic disease, expert participants highlight cornerstone frontline therapies in follicular lymphoma.

Matthew Matasar, MD and Laurie Sehn, MD, share insight on available therapies for relapsed or refractory follicular lymphoma and reflect on factors that help in treatment selection.

Switching to the paradigm of multiply relapsed follicular lymphoma, expert participants discuss the rationale behind and use of PI3k- and EZH2- targeted therapies.

Shared insight on the development and use of CAR T-cell therapy in patients with multiply relapsed follicular lymphoma.

Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.

Experts Matthew Matasar, MD and Laurie Sehn, MD, nuance the adverse event profiles of bispecific antibody therapies and consider how these will help inform treatment decisionmaking.

Closing out their discussion on bispecific antibody therapies, Matthew Matasar, MD and Laurie Sehn, MD, consider ongoing clinical trials and real-world use of these novel agents.